AllWays Formulary Changes Effective 1/1/22

1. Prefer Advair HFA, Advair Diskus, and Symbicort over fluticasone/salmeterol HFA, fluticasone/salmeterol Diskus, and budesonide-formoterol from formulary
   ▪ Move Symbicort to generic tier
   ▪ Move fluticasone/salmeterol HFA, fluticasone/salmeterol Diskus, and budesonide-formoterol to non-formulary

2. Prefer Ajovy and Emgality over Aimovig.
   ▪ Move all Emgality strengths to preferred tier
   ▪ Move Aimovig to non-formulary

3. Update the quantity limit for Reyvow 50mg
   ▪ Quantity limit will be 4 tablets initially, then 8 tablets per month

4. Prefer Wakix over Xywav and Xyrem
   ▪ Add Wakix to preferred specialty tier
   ▪ Update criteria to require failure of Wakix before Xywav or Xyrem

5. Prefer Vumerity over bafiertam
   ▪ Add Vumerity to preferred specialty
   ▪ Move bafiertam to non-formulary
   ▪ Add PA to Zeposia to allow coverage for multiple sclerosis diagnosis

6. Prefer Praluent over Repatha
   ▪ Move Repatha to non-formulary

7. Prefer both Entresto and Verquvo
   ▪ Add Verquvo to preferred tier with step through Entresto
   ▪ Keep PA on Entresto and remove quantity limit

8. Prefer Bosulif, Tasigna, and Sprycel over Iclusig
   ▪ Will be reflected as preferred within formulary display

9. Prefer Kesimpta, Ocrevus, and Tysabri over Lemtrada
   ▪ Add Kesimpta, Ocrevus, and Tysabri to the pharmacy benefit on the preferred specialty tier
   ▪ Add Lemtrada to the pharmacy benefit on the non-preferred specialty tier

10. Low Cost Generics
    ▪ Updates are being made to our low-cost generic list. This will only impact members on one of our 6 Tier plans.